This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ResMed (RMD) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 37.11% and 8.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Patterson Cos. (PDCO) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Patterson Cos. (PDCO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top 7 Stocks Set to Beat on Earnings Today After Market
by Nalak Das
Seven top-ranked companies are poised to beat on earnings today after the closing bell.
Medical Products Stock Earnings on Aug 5: RMD, ABC & More
by Urmimala Biswas
Many Medical Product stocks might have succeeded in mitigating coronavirus-led downsides banking on huge market adoption of their COVID-19-related healthcare-support products in the second quarter.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Is a Surprise Coming for ResMed (RMD) This Earnings Season?
by Zacks Equity Research
ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can ResMed (RMD) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Idexx (IDXX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Idexx (IDXX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Canopy Growth (CGC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) second-quarter results benefit from solid segmental performance.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q2.
LabCorp (LH) Beats Q2 Earnings Estimates, Margins Decline
by Zacks Equity Research
LabCorp (LH) witnesses a 20.7% decline in organic volume, partially offset by acquisition volume growth of 1.2%.
Has ResMed (RMD) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (RMD) Outperforming Other Medical Stocks This Year?
Ecolab (ECL) Earnings and Revenues Lag Estimates in Q2
by Zacks Equity Research
Ecolab's (ECL) second-quarter results reflect weakness in the Global Industrial and Institutional segments.
Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
by Zacks Equity Research
Despite coronavirus-hit sales, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q2. Regulatory approvals look encouraging.
Quest Diagnostics' (DGX) Q2 Earnings Beat, Volume Declines
by Zacks Equity Research
Following the guidance withdrawal last quarter, Quest Diagnostics (DGX) provides its full-year projection alongside Q2 earnings release.
Align Technology (ALGN) Earnings Fall Shy of Estimates in Q2
by Zacks Equity Research
Align Technology's (ALGN) segments report COVID-19-led lower sales across major geographies.
Neogen (NEOG) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Neogen's (NEOG) Animal Safety revenues improve in the fourth quarter on strong sales of cleaners, disinfectants and sanitizers.
Thermo Fisher (TMO) Q2 Earnings Beat on COVID-19-Led Sales
by Zacks Equity Research
We are encouraged about Thermo Fisher's (TMO) exceptionally strong year-over-year revenue growth at Life Sciences Solutions segment.
Intuitive Surgical (ISRG) Q2 Earnings Top Estimates, Down Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect weak performance across all businesses and lower revenues.
3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD)
by Zacks Equity Research
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPME
Patterson Cos. (PDCO) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Patterson Cos. (PDCO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.